Navigating antibiotic therapy in acute cholangitis: Best practices and new insights
Journal of Hepato-Biliary-Pancreatic Sciences · 2025-01 · 32 (1) · 44-57
DOI: 10.1002/jhbp.12087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, online erschienen am 13.11.2024. Verfasst von Sakue Masuda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan. Hauptthemen laut MEDLINE: Cholangitis, Anti-Bacterial Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Globally, antibiotic resistance is linked to increased morbidity, mortality, and healthcare costs, which necessitates further research on optimal antibiotic usage. Acute cholangitis (AC), a common cause of community‐acquired bacteremia, often requires antimicrobial therapy. Therefore, studying the appropriate use of antibiotics for AC is considered crucial for suppressing the emergence of resistant bacteria and reducing adverse antibiotic‐associated events. The Tokyo Guidelines 2018 (TG18) recommend 4–7 days of antibiotics post‐biliary drainage. However, this lacks strong evidence and is based primarily on various evidence and expert opinions. Recent retrospective studies advocate for a shorter 1–3‐day antibiotic course for AC, thereby prompting a need to reassess the treatment duration to balance therapeutic efficacy and minimize resistance and adverse effects. Choosing the appropriate duration and antibiotics based on susceptibility to pathogens causing cholangitis is important. Awareness of local resistance patterns and understanding patients' risks of resistant pathogens are prerequisite for effective treatment. We must explore the applicability of these guidelines in specific scenarios such as severe AC, positive blood cultures, fever, or hilar biliary obstructions due to malignancy. This comprehensive review considers both the duration and type of antibiotics and aims to enhance treatment outcomes while reducing the risk of resistant bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan.
- Cancer Care Promotion Center, University of Fukui Hospital, Fukui, Japan.
- Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan.
ORCID-Profile: Sakue Masuda, Kazuya Koizumi
Zitieren
APA
Masuda, S., Imamura, Y., Jinushi, R., Kimura, K., Ryozawa, S., & Koizumi, K. (2025). Navigating antibiotic therapy in acute cholangitis: Best practices and new insights. Journal of Hepato-Biliary-Pancreatic Sciences, 32(1), 44-57. https://doi.org/10.1002/jhbp.12087
Vancouver
Masuda S, Imamura Y, Jinushi R, Kimura K, Ryozawa S, Koizumi K. Navigating antibiotic therapy in acute cholangitis: Best practices and new insights. Journal of Hepato-Biliary-Pancreatic Sciences. 2025;32(1):44-57. doi:10.1002/jhbp.12087
BibTeX
@article{Masuda2025,
author = {Masuda, Sakue and Imamura, Yoshinori and Jinushi, Ryuhei and Kimura, Karen and Ryozawa, Shomei and Koizumi, Kazuya},
title = {Navigating antibiotic therapy in acute cholangitis: Best practices and new insights},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
volume = {32},
number = {1},
pages = {44--57},
doi = {10.1002/jhbp.12087}
}
EUVIMED